Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genzyme, a Sanofi Company
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Histopathologically documented invasive epithelial ovarian carcinoma, cancer of the fallopian tube or the peritoneum refractory to platinum-based chemotherapy or with partially platinum sensitive disease.
Planned therapy with pegylated liposomal doxorubicin 50 mg/m² for recurrent platinum-refractory ovarian cancer.
Patients must have received at least one previous platinum- and taxane-based chemotherapy regimen.
You may not be if
Brain metastases or spinal cord compression, unless treated at least 4 weeks before first dose and stable without steroid treatment for 10 days
Any concomitant medications that may cause QTc prolongation or induce Torsades de Pointes or induce CYP3A4 function
Treatment with mouse-antibodies in patients with evaluable disease and CA-125 progressive disease in the last 3 months. These patients are only eligible in case of measurable disease according to RECIST or cytological/histological proven relapse
More than two prior lines of chemotherapy.
Any chemotherapy or other systemic anti-cancer therapy within four weeks prior to randomization.
Radiation therapy within the last 4 weeks prior to randomization (with the exception of palliative radiotherapy
Clareo Health | Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD)
